Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
Abstract
:1. Introduction
2. Experimental Section
2.1. Nivolumab Cohort
2.2. Chemotherapy Cohort
2.3. Immunohistochemistry (IHC)
2.4. IHC Scoring
2.5. Statistical Analysis
3. Results
3.1. The Expression of B7-H4 Was Associated with Lower Progression-Free Survival in the Nivolumab Cohort
3.2. B7-H4 Expression Was Not Associated with Response or Survival in the Chemotherapy Cohort
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Iafolla, M.A.J.; Juergens, R.A. Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. Front. Oncol. 2017, 7, 67. [Google Scholar] [CrossRef] [PubMed]
- Dal Bello, M.G.; Alama, A.; Coco, S.; Vanni, I.; Grossi, F. Understanding the checkpoint blockade in lung cancer immunotherapy. Drug Discov. Today 2017, 22, 1266–1273. [Google Scholar] [CrossRef] [PubMed]
- Hirsch, F.R.; McElhinny, A.; Stanforth, D.; Ranger-Moore, J.; Jansson, M.; Kulangara, K.; Richardson, W.; Towne, P.; Hanks, D.; Vennapusa, B.; et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J. Thorac. Oncol. 2017, 12, 208–222. [Google Scholar] [CrossRef] [PubMed]
- Ilie, M.; Long-Mira, E.; Bence, C.; Butori, C.; Lassalle, S.; Bouhlel, L.; Fazzalari, L.; Zahaf, K.; Lalvée, S.; Washetine, K.; et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: A potential issue for anti-PD-L1 therapeutic strategies. Ann. Oncol. 2016, 27, 147–153. [Google Scholar] [CrossRef]
- Grigg, C.; Rizvi, N.A. PD-L1 biomarker testing for non-small cell lung cancer: Truth or fiction? J. Immunother. Cancer 2016, 4, 48. [Google Scholar] [CrossRef]
- Zang, X.; Allison, J.P. The B7 family and cancer therapy: Costimulation and coinhibition. Clin. Cancer Res. 2007, 13 Pt 1, 5271–5279. [Google Scholar] [CrossRef]
- Kerr, K.M.; Hirsch, F.R. Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe? Arch. Pathol. Lab. Med. 2016, 140, 326–331. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Munari, E.; Zamboni, G.; Marconi, M.; Sommaggio, M.; Brunelli, M.; Martignoni, G.; Netto, G.J.; Moretta, F.; Mingari, M.C.; Salgarello, M.; et al. PD-L1 expression heterogeneity in non-small cell lung cancer: Evaluation of small biopsies reliability. Oncotarget 2017, 8, 90123–90131. [Google Scholar] [CrossRef]
- Latchman, Y.; Wood, C.R.; Chernova, T.; Chaudhary, D.; Borde, M.; Chernova, I.; Iwai, Y.; Long, A.J.; Brown, J.A.; Nunes, R.; et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2001, 2, 261–268. [Google Scholar] [CrossRef]
- Xiao, Y.; Yu, S.; Zhu, B.; Bedoret, D.; Bu, X.; Francisco, L.M.; Hua, P.; Duke-Cohan, J.S.; Umetsu, D.T.; Sharpe, A.H.; et al. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J. Exp. Med. 2014, 211, 943–959. [Google Scholar] [CrossRef]
- Xu, H.; Chen, X.; Tao, M.; Chen, K.; Chen, C.; Xu, G.; Li, W.; Yuan, S.; Mao, Y. B7-H3 and B7-H4 are independent predictors of a poor prognosis in patients with pancreatic cancer. Oncol. Lett. 2016, 11, 1841–1846. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chapoval, A.I.; Ni, J.; Lau, J.S.; Wilcox, R.A.; Flies, D.B.; Liu, D.; Dong, H.; Sica, G.L.; Zhu, G.; Tamada, K.; et al. B7-H3: A costimulatory molecule for T cell activation and IFN-gamma production. Nat. Immunol. 2001, 2, 269–274. [Google Scholar] [CrossRef] [PubMed]
- Leitner, J.; Klauser, C.; Pickl, W.F.; Stöckl, J.; Majdic, O.; Bardet, A.F.; Kreil, D.P.; Dong, C.; Yamazaki, T.; Zlabinger, G.; et al. B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction. Eur. J. Immunol. 2009, 39, 1754–1764. [Google Scholar] [CrossRef] [PubMed]
- Prasad, D.V.; Nguyen, T.; Li, Z.; Yang, Y.; Duong, J.; Wang, Y.; Dong, C. Murine B7-H3 is a negative regulator of T cells. J. Immunol. 2004, 173, 2500–2506. [Google Scholar] [CrossRef] [PubMed]
- Yan, R.; Yang, S.; Gu, A.; Zhan, F.; He, C.; Qin, C.; Zhang, X.; Feng, P. Murine b7-h3 is a co-stimulatory molecule for T cell activation. Monoclon. Antibodies Immunodiagn. Immunother. 2013, 32, 395–398. [Google Scholar] [CrossRef] [PubMed]
- Inamura, K.; Yokouchi, Y.; Kobayashi, M.; Sakakibara, R.; Ninomiya, H.; Subat, S.; Nagano, H.; Nomura, K.; Okumura, S.; Shibutani, T.; et al. Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. Lung Cancer 2017, 103, 44–51. [Google Scholar] [CrossRef] [PubMed]
- Wu, S.; Zhao, X.; Wu, S.; Du, R.; Zhu, Q.; Fang, H.; Zhang, X.; Zhang, C.; Zheng, W.; Yang, J.; et al. Overexpression of B7-H3 correlates with aggressive clinicopathological characteristics in non-small cell lung cancer. Oncotarget 2016, 7, 81750–81756. [Google Scholar] [CrossRef] [Green Version]
- He, C.; Qiao, H.; Jiang, H.; Sun, X. The inhibitory role of b7-h4 in antitumor immunity: Association with cancer progression and survival. Clin. Dev. Immunol. 2011, 2011, 695834. [Google Scholar] [CrossRef]
- Choi, I.H.; Zhu, G.; Sica, G.L.; Strome, S.E.; Cheville, J.C.; Lau, J.S.; Zhu, Y.; Flies, D.B.; Tamada, K.; Chen, L. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J. Immunol. 2003, 171, 4650–4654. [Google Scholar] [CrossRef]
- Qian, Y.; Sang, Y.; Wang, F.X.; Hong, B.; Wang, Q.; Zhou, X.; Weng, T.; Wu, Z.; Zheng, M.; Zhang, H.; et al. Prognostic significance of B7-H4 expression in matched primary pancreatic cancer and liver metastases. Oncotarget 2016, 7, 72242–72249. [Google Scholar] [CrossRef] [Green Version]
- Smith, J.B.; Stashwick, C.; Powell, D.J. B7-H4 as a potential target for immunotherapy for gynecologic cancers: A closer look. Gynecol. Oncol. 2014, 134, 181–189. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tan, Z.; Shen, W. Prognostic role of B7-H4 in patients with non-small cell lung cancer: A meta-analysis. Oncotarget 2017, 8, 27137–27144. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Song, X.; Shao, Y.; Gu, W.; Xu, C.; Mao, H.; Pei, H.; Jiang, J. Prognostic role of high B7-H4 expression in patients with solid tumors: A meta-analysis. Oncotarget 2016, 7, 76523–76533. [Google Scholar] [CrossRef] [PubMed]
- Altan, M.; Pelekanou, V.; Schalper, K.A.; Toki, M.; Gaule, P.; Syrigos, K.; Herbst, R.S.; Rimm, D.L. B7-H3 expression in NSCLC and its association with B7-H4, PD-L1 and tumor-infiltrating lymphocytes. Clin. Cancer Res. 2017, 23, 5202–5209. [Google Scholar] [CrossRef] [PubMed]
- Available online: https://clinicaltrials.gov/ct2/show/NCT02475382 (accessed on 5 September 2019).
- Crinò, L.; Bidoli, P.; Delmonte, A.; Grossi, F.; De Marinis, F.; Sperandi, F.; Vitiello, F.; Vitali, M.; Soto Parra, H.J.; Scagnoli, S.; et al. Italian cohort of nivolumab Expanded Access Programme (EAP): Preliminary data from a real-world population. J. Clin. Oncol. 2016, 34, 3067. [Google Scholar] [CrossRef]
- Available online: https://clinicaltrials.gov/ct2/show/NCT02055144 (accessed on 5 September 2019).
- Grossi, F.; Rijavec, E.; Genova, C.; Barletta, G.; Biello, F.; Maggioni, C.; Burrafato, G.; Sini, C.; Dal Bello, M.G.; Meyer, K.; et al. Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy. Br. J. Cancer 2017, 116, 36–43. [Google Scholar] [CrossRef] [PubMed]
- Neuman, T.; London, M.; Kania-Almog, J.; Litvin, A.; Zohar, Y.; Fridel, L.; Sandbank, J.; Barshak, I.; Vainer, G.W. A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana’s Platform. J. Thorac. Oncol. 2016, 11, 1863–1868. [Google Scholar] [CrossRef]
- Phillips, T.; Simmons, P.; Inzunza, H.D.; Cogswell, J.; Novotny, J., Jr.; Taylor, C.; Zhang, X. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl. Immunohistochem. Mol. Morphol. 2015, 23, 541–549. [Google Scholar] [CrossRef]
- Borghaei, H.; Paz-Ares, L.; Horn, L.; Spigel, D.R.; Steins, M.; Ready, N.E.; Chow, L.Q.; Vokes, E.E.; Felip, E.; Holgado, E.; et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015, 373, 1627–1639. [Google Scholar] [CrossRef]
- Brahmer, J.; Reckamp, K.L.; Baas, P.; Crinò, L.; Eberhardt, W.E.; Poddubskaya, E.; Antonia, S.; Pluzanski, A.; Vokes, E.E.; Holgado, E.; et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015, 373, 123–135. [Google Scholar] [CrossRef]
- Herbst, R.S.; Baas, P.; Kim, D.W.; Felip, E.; Pérez-Gracia, J.L.; Han, J.Y.; Molina, J.; Kim, J.H.; Arvis, C.D.; Ahn, M.J.; et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016, 387, 1540–1550. [Google Scholar] [CrossRef]
- Dong, Y.; Sun, Q.; Zhang, X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget 2017, 8, 2171–2186. [Google Scholar] [CrossRef] [PubMed]
- Wang, X.; Wang, T.; Xu, M.; Xiao, L.; Luo, Y.; Huang, W.; Zhang, Y.; Geng, W. B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas. Hum. Immunol. 2014, 75, 1203–1209. [Google Scholar] [CrossRef] [PubMed]
- Zhao, L.W.; Li, C.; Zhang, R.L.; Xue, H.G.; Zhang, F.X.; Zhang, F.; Gai, X.D. B7-H1 and B7-H4 expression in colorectal carcinoma: Correlation with tumor FOXP3(+) regulatory T-cell infiltration. Acta Histochem. 2014, 116, 1163–1168. [Google Scholar] [CrossRef] [PubMed]
- Kryczek, I.; Wei, S.; Zhu, G.; Myers, L.; Mottram, P.; Cheng, P.; Chen, L.; Coukos, G.; Zou, W. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 2007, 67, 8900–8905. [Google Scholar] [CrossRef] [PubMed]
- Ye, Z.; Zheng, Z.; Li, X.; Zhu, Y.; Zhong, Z.; Peng, L.; Wu, Y. B7-H3 Overexpression Predicts Poor Survival of Cancer Patients: A Meta-Analysis. Cell. Physiol. Biochem. 2016, 39, 1568–1580. [Google Scholar] [CrossRef] [PubMed]
Clinical Characteristics | Nivolumab Cohort | Chemotherapy Cohort |
---|---|---|
n (%) | n (%) | |
Patients | 46 | 27 |
Gender | ||
Male | 34 (73.9) | 20 (74.1) |
Female | 12 (26.1) | 7 (25.9) |
Age (year) | ||
Range | 44–82 | 46–81 |
Median | 70 | 69 |
Smoking habit | ||
Current | 13 (28.3) | 12 (44.4) 1 |
Former | 24 (52.2) | 12 (44.4) 1 |
Never | 9 (19.5) | 3 (11.1) 1 |
Histology | ||
Non-squamous | 35 (76.1) | 27 (100.0) |
Squamous | 11 (23.9) | 0 (0.0) |
Stage | ||
IIIB | 2 (4.4) | 0 (0.0) |
IV | 44 (95.6) | 27 (100.0) |
ECOG PS | ||
0 | 17 (37.0) | 6 (22.2) |
1 | 26 (56.5) | 21 (77.8) |
2 | 3 (6.5) | 0 (0.0) |
Previous lines of treatment | ||
Range | 1–6 | - |
Median | 2 | - |
EGFR mutation | ||
Yes | 3 (8.6) 2,4 | 1 (3.7) 3 |
No | 32 (91.4) 4 | 26 (96.3) |
ALK rearrangement | ||
Yes | 0 (0.0) 4 | 0 (0.0) |
No | 35 (100.0) 4 | 27 (100.0) |
Nivolumab Cohort n (%) | |||||||
Biomarkers | <1% | 1%–9% | 10%–49% | ≥50% | ND | Positive Total | Negative Total |
PD-L1 | 38 (82.6) | 4 (8.7) | 2 (4.3) | 1 (2.2) | 1 (2.2) | 7 (15.6) | 38 (84.4) |
PD-L2 | 38 (82.6) | 2 (4.3) | 5 (10.9) | 1 (2.2) | 0 (0.0) | 8 (17.4) | 38 (82.6) |
PD-1 | 13 (28.3) | 8 (17.4) | 5 (10.9) | 18 (39.1) | 2 (4.3) | 31 (70.5) | 13 (29.5) |
B7-H3 | 40 (87.0) | 2 (4.3) | 3 (6.5) | 1 (2.2) | 0 (0.0) | 6 (13.0) | 40 (87.0) |
B7-H4 | 29 (63.0) | 5 (10.9) | 4 (8.7) | 8 (17.4) | 0 (0.0) | 17 (27.0) | 29 (63.0) |
Chemotherapy Cohort n (%) | |||||||
Biomarkers | <1% | 1%–9% | 10%–49% | ≥50% | ND | Positive Total | Negative Total |
PD-L1 | 21 (77.8) | 5 (18.5) | 1 (3.7) | 0 (0.0) | 0 (0.0) | 6 (22.2) | 21 (77.8) |
B7-H4 1 | 12 (44.4) | 3 (11.1) | 3 (11.1) | 9 (33.3%) | 0 (0.0%) | 15 (55.6) | 12 (44.4) |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Genova, C.; Boccardo, S.; Mora, M.; Rijavec, E.; Biello, F.; Rossi, G.; Tagliamento, M.; Dal Bello, M.G.; Coco, S.; Alama, A.; et al. Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. J. Clin. Med. 2019, 8, 1566. https://doi.org/10.3390/jcm8101566
Genova C, Boccardo S, Mora M, Rijavec E, Biello F, Rossi G, Tagliamento M, Dal Bello MG, Coco S, Alama A, et al. Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. Journal of Clinical Medicine. 2019; 8(10):1566. https://doi.org/10.3390/jcm8101566
Chicago/Turabian StyleGenova, Carlo, Simona Boccardo, Marco Mora, Erika Rijavec, Federica Biello, Giovanni Rossi, Marco Tagliamento, Maria Giovanna Dal Bello, Simona Coco, Angela Alama, and et al. 2019. "Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab" Journal of Clinical Medicine 8, no. 10: 1566. https://doi.org/10.3390/jcm8101566